Details for Patent: 8,946,250

Which drugs does patent 8,946,250 protect, and when does it expire?

Patent 8,946,250 protects BRAFTOVI and is included in one NDA.

This patent has twenty-one patent family members in nineteen countries.

Summary for Patent: 8,946,250

Title:	3,4-diarylpyrazoles as protein kinase inhibitors
Abstract:	3,4-diarylpyrazole derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. ##STR00001##
Inventor(s):	Pulici; Maurizio (Caponago, IT), Zuccotto; Fabio (Milan, IT), Traquandi; Gabriella (Milan, IT), Biondaro; Sonia (Ronca, IT), Trifiro'; Paolo (Genoa, IT), Badari; Alessandra (Vedano al Lambro, IT), Nuvoloni; Stefano (Genoa, IT), Cervi; Giovanni (Como, IT), Marchionni; Chiara (Milan, IT), Modugno; Michele (Cernusco sul Naviglio, IT)
Assignee:	Nerviano Medical Sciences S.R.L. (Nerviano (MI), IT)
Application Number:	13/970,854
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,946,250

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-001	Jun 27, 2018		DISCN	Yes	No			Y	Y
Array Biopharma Inc	BRAFTOVI	encorafenib	CAPSULE;ORAL	210496-002	Jun 27, 2018		RX	Yes	Yes			Y	Y

Foreign Priority and PCT Information for Patent: 8,946,250

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	08161076	Jul 24, 2008

International Family Members for US Patent 8,946,250

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E557015
Australia	2009273197
Brazil	PI0916356
Canada	2731146